HLB Wins 'Sustainability Report Award' at Sustainability Competition

HLB announced on the 28th that it was selected as an outstanding company at the 2023 Korea Sustainability Conference and received the 'Sustainability Report Award.'

Kim Jung-il, Executive Director of HLB's Business Strategy Team, is receiving the Sustainability Report Award from the Korea Standards Association.
[Photo by HLB]

The Korea Sustainability Report Award (KRCA) is based on the Global Reporting Initiative (GRI), a global ESG (Environmental, Social, Governance) information disclosure guideline, and stakeholders evaluate and award ESG reports of domestic companies. It has been held since 2008 and is now in its 16th year.

This year, out of 362 domestic reports, a total of 19 were selected as outstanding reports. Among them, considering the global trend of expanding ESG disclosure requirements from large corporations to small and medium-sized enterprises, HLB became the first recipient in the newly established SME category this year. The company also added that among pharmaceutical and bio companies, only HLB and Hanmi Pharmaceutical received the award for outstanding reports.

HLB, which completed the global Phase 3 clinical trial of the liver cancer new drug 'Lenvatinib' and is aiming to become the first domestic company to receive approval from the U.S. Food and Drug Administration (FDA) for an anticancer new drug, is continuing proactive steps in ESG management to become a company that meets global standards, as the approval review deadline for Lenvatinib is set for May next year.

Following the establishment of the ESG management team under the group in 2021, HLB has installed a 100 kW capacity solar power generation facility on the roof of its Sejong headquarters to prepare for climate change and secured over 600 tons of carbon emission rights through the voluntary carbon market (VCM) to offset emissions, striving to realize 'carbon neutrality by 2045.' The company has also maintained steady donation activities and support projects for children in need through organizations such as the Green Umbrella Children’s Foundation, local university medical foundations, and disability groups for several years. It has been recognized as a 'Family-Friendly Excellent Company' by the Ministry of Gender Equality and Family, one of the 'Top 150 Sustainable Leading Companies in Korea' selected by the global market research firm Statista, and has also been awarded the 'K-ESG Management Award' hosted by Dong-A Ilbo.

Im Tae-hoon, head of HLB Group’s ESG management team, said, “With the recent trend of mandatory ESG information disclosure, ESG management is no longer optional but essential for companies, and this applies to new drug development companies as well. As a global healthcare company, we will actively participate not only in new drug development but also in governance improvement and social contribution to establish ourselves as a global company that enriches human life.”

This content was produced with the assistance of AI translation services.